Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Average Rating of “Hold” by Brokerages

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have received an average rating of “Hold” from the five research firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $8.10.

Several research firms have commented on RXRX. Needham & Company LLC reiterated a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. Morgan Stanley increased their price target on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a report on Thursday, May 14th. JPMorgan Chase & Co. reduced their price objective on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Finally, Wall Street Zen downgraded Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 30,000 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $3.68, for a total value of $110,400.00. Following the sale, the director owned 6,169,863 shares in the company, valued at $22,705,095.84. This trade represents a 0.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 23,588 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $3.58, for a total transaction of $84,445.04. Following the completion of the transaction, the chief executive officer owned 2,175,796 shares in the company, valued at approximately $7,789,349.68. The trade was a 1.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 121,937 shares of company stock valued at $421,574 in the last 90 days. Company insiders own 6.65% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Brighton Jones LLC lifted its stake in shares of Recursion Pharmaceuticals by 49.4% during the 4th quarter. Brighton Jones LLC now owns 20,261 shares of the company’s stock worth $137,000 after purchasing an additional 6,699 shares during the last quarter. Royal Bank of Canada grew its stake in Recursion Pharmaceuticals by 627.6% in the first quarter. Royal Bank of Canada now owns 269,013 shares of the company’s stock valued at $1,423,000 after purchasing an additional 232,038 shares during the last quarter. AQR Capital Management LLC bought a new position in Recursion Pharmaceuticals in the first quarter worth about $890,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Recursion Pharmaceuticals by 7.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company’s stock valued at $953,000 after buying an additional 12,372 shares during the last quarter. Finally, Focus Partners Wealth purchased a new stake in shares of Recursion Pharmaceuticals during the first quarter valued at about $77,000. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Price Performance

Shares of Recursion Pharmaceuticals stock remained flat at $3.80 during trading on Friday. The company had a trading volume of 32,626,246 shares, compared to its average volume of 20,606,352. Recursion Pharmaceuticals has a 12 month low of $2.77 and a 12 month high of $7.18. The stock has a 50-day simple moving average of $3.31 and a 200-day simple moving average of $3.66. The stock has a market cap of $2.01 billion, a PE ratio of -3.17 and a beta of 1.00. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. The firm had revenue of $6.47 million during the quarter, compared to the consensus estimate of $15.78 million. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. The company’s revenue for the quarter was down 56.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.50) EPS. On average, equities analysts predict that Recursion Pharmaceuticals will post -0.99 earnings per share for the current fiscal year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.